Table 3.
Survival outcome of pancreatic cancer patients according to chemotherapy agents
| Chemotherapy agents | N | Median survival time, months (95% CI) | HR (95% CI) | P-value | Adjusted HRa (95% CI) | P-value | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Gemcitabine-treated | No | 34 | 3.3 (1.8–4.8) | 1 | 1 | ||
| Yes | 620 | 6.7 (6.1–7.4) | 0.40 (0.28–0.57) | <0.001 | 0.63 (0.43–0.91) | 0.014 | |
| S-1-treated | No | 405 | 5.2 (4.8–5.7) | 1 | 1 | ||
| Yes | 249 | 8.6 (7.6–9.6) | 0.55 (0.46–0.65) | <0.001 | 0.56 (0.480.67) | <0.001 | |
| Cisplatin-treated | No | 311 | 4.5 (4.0–5.1) | 1 | 1 | ||
| Yes | 343 | 8.2 (7.6–8.7) | 0.50 (0.43–0.59) | <0.001 | 0.61 (0.51–0.73) | <0.001 | |
| 5-FU-treated | No | 460 | 5.5 (5.0–6.0) | 1 | 1 | ||
| Yes | 194 | 9.0 (7.6–10.5) | 0.58 (0.49–0.69) | <0.001 | 0.65 (0.54–0.78) | <0.001 | |
| Other agents-treatedb | No | 546 | 5.7 (5.1–6.3) | 1 | 1 | ||
| Yes | 108 | 10.3 (9.2–11.4) | 0.58 (0.43–0.75) | <0.001 | 0.64 (0.51–0.80) | <0.001 | |
Notes:
a
Adjusted for sex, age, Charlson comorbidity, ECOG PS, site of metastatic organ, and smoking history.
b
Other agents included chemotherapeutic agents with irinotecan, oxaliplatin, nab-paclitaxel, and erlotinib.
Abbreviation: ECOG PS, European Cooperative Oncology Group performance status.